Verdicts & Settlements

Sellers of blood-thinner drug to settle about 25,000 suits for $775M

  • Print.


Image from

The sellers of the blood thinner Xarelto have agreed to pay $775 million to settle about 25,000 lawsuits claiming the companies failed to warn the drug can cause potentially fatal bleeding.

Johnson & Johnson and Bayer agreed to the settlement Monday, report the New York Times, the Wall Street Journal, Reuters and USA Today. They each will pay half.

The companies did not admit liability, and they had won six cases that went to trial. A new antidote approved by the Food and Drug Administration last year can help stop bleeding in Xarelto patients.

Johnson & Johnson’s pharmaceutical division, Janssen, said in a statement it was settling because of the time and resources needed for litigation. “What’s the bottom line? We stand behind Xarelto and are eager and excited to move forward,” the statement said.

Bayer also released a statement saying it remains committed to patients who have been prescribed Xarelto.

The Wall Street Journal noted that Bayer is fighting claims over its Roundup weed killer, and Johnson & Johnson is facing claims over its baby powder.

See also: “Drugmaker claims #killinnazis Instagram posts are part of lawyers’ ‘xenophobic’ strategy” “Judge punishes lawyer for using hashtag #killinnazis, tosses $27.8M Xarelto verdict on other grounds” “Judge slashes $211M from punitive award in Roundup cancer case” “Federal judge sanctions lead lawyer in Roundup trial for opening statement ‘misconduct’” “Johnson & Johnson ordered to pay nearly $4.7B in talcum powder case” “Jury awards $55M to woman who claimed Johnson & Johnson talcum powder caused her cancer”

Give us feedback, share a story tip or update, or report an error.